Glyoxalase I Glu111Ala polymorphism in patients with breast cancer

Cancer Invest. 2009 Jul;27(6):655-60. doi: 10.1080/07357900802350822.

Abstract

Effect of advanced glycation end products (AGEs) in the pathogenesis of cancer could be diminished by interaction with soluble RAGE or by reducing AGE-precursors via glyoxalase I. Glu111Ala polymorphism of glyoxalase I gene, AGEs, and sRAGE serum levels were studied in 113 breast cancer patients and in 58 controls. Higher frequency of the mutated C allele was found in patients with negative estrogen receptors and in patients in clinical stage III compared to controls (P< 0.05). The presence of the C allele could represent a negative prognostic factor; however, further studies are needed to confirm this hypothesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Breast Neoplasms / enzymology
  • Breast Neoplasms / genetics*
  • Breast Neoplasms / pathology
  • Case-Control Studies
  • Female
  • Gene Expression Regulation, Enzymologic*
  • Gene Expression Regulation, Neoplastic*
  • Gene Frequency
  • Genotype
  • Glycation End Products, Advanced / blood
  • Humans
  • Lactoylglutathione Lyase / genetics*
  • Middle Aged
  • Neoplasm Staging
  • Phenotype
  • Polymorphism, Single Nucleotide*
  • Prognosis
  • Receptor for Advanced Glycation End Products
  • Receptors, Estrogen / analysis
  • Receptors, Immunologic / blood

Substances

  • Glycation End Products, Advanced
  • Receptor for Advanced Glycation End Products
  • Receptors, Estrogen
  • Receptors, Immunologic
  • Lactoylglutathione Lyase